Low-Dose GCC Agonist Peptide Formulation Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of guanylate cyclase C peptide agonists face challenges due to chemical and physical instability, leading to ineffective treatment options for gastrointestinal disorders.
Innovation Solution
Development of low-dose formulations stabilized against chemical degradation, using pharmaceutically acceptable excipients and specific GCC agonist peptides that resist degradation, such as analogs of uroguanylin and bacterial ST peptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional formulations of guanylate cyclase C peptide agonists are used, then the peptide can be administered, but the formulation suffers from chemical and physical instability leading to degradation
Solution Approach 1:
The patent employs stabilizing excipients as intermediary substances that protect the peptide from degradation. These excipients act as mediators between the peptide and the environment, preventing direct harmful interactions that would cause chemical or physical degradation while allowing the peptide to remain bioactive.
Solution Approach 2:
The formulation modifies physical and chemical parameters such as pH, ionic strength, and molecular concentration to optimize peptide stability. By adjusting these parameters within specific ranges, the formulation maintains the peptide in a stable state that resists degradation while preserving its pharmacological activity.
2Reliability
If high doses of peptide agonists are used to overcome instability, then adequate therapeutic effect may be achieved, but side effects increase
Solution Approach 1:
The stabilized formulation enables the use of lower-than-expected doses of the peptide agonist to achieve therapeutic effect. Because the formulation protects the peptide from degradation, even partial amounts of the stable peptide are sufficient to produce the desired therapeutic outcome without triggering excessive side effects.
Solution Approach 2:
The formulation accepts that individual peptide molecules have limited lifetimes due to eventual degradation, but through continuous stabilization mechanisms and optimized dosing, maintains effective concentrations throughout the therapeutic window, avoiding the need for excessive dosing that would increase side effects.
3Reliability
If peptide formulations are stabilized against degradation, then efficacy improves, but formulation complexity increases
Solution Approach 1:
The formulation achieves stabilization by optimizing parameters within relatively narrow ranges rather than employing complex multi-component systems. By carefully controlling pH, ionic strength, and concentration parameters, the formulation maintains peptide stability without requiring elaborate stabilization mechanisms.
Solution Approach 2:
The formulation applies stabilization strategies locally to the peptide molecule and its immediate microenvironment rather than throughout the entire formulation system. This targeted approach stabilizes the peptide where it is most vulnerable to degradation while minimizing the need for system-wide complexity.
Data Source
AI summary
The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.